SMMT

SMMT

USD

Summit Therapeutics Inc. Common Stock

$17.490-0.290 (-1.631%)

实时价格

Healthcare
生物技术
美国

价格图表

Loading Chart...

关键指标

市场指标
公司基本面
交易统计

市场指标

开盘价

$17.780

最高价

$18.120

最低价

$17.370

成交量

2.88M

公司基本面

市值

13.0B

所属行业

生物技术

国家/地区

United States

交易统计

平均成交量

4.10M

交易所

NGM

货币

USD

52周价格范围

最低价 $15.55当前价 $17.490最高价 $36.91

相关新闻

BusinessWire

Summit Therapeutics to Present at Upcoming Investor Conferences

Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") today announced that it will participate in and present at four upcoming investor conferences during the remainder of this year. Members of the

查看更多
Summit Therapeutics to Present at Upcoming Investor Conferences
BusinessWire

Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025

Conducted by Akeso, HARMONi-A Represents the First Statistically Significant OS Benefit Achieved in a Phase III Study by an Ivonescimab-Containing Regimen Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the

查看更多
Overall Survival Data from HARMONi-A, Featuring Ivonescimab in Combination with Chemotherapy vs. Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC in China, to be Showcased at SITC 2025
Analyst Upgrades

Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target

Guggenheim analyst Brad Canino reiterates Summit Therapeutics with a Buy and maintains $40 price target.

查看更多
Guggenheim Reiterates Buy on Summit Therapeutics, Maintains $40 Price Target
BusinessWire

Summit Therapeutics Raises $500 Million in Private Placement

Fundraise Led by Leading Biopharma Institutional Investors & Insiders $500 Million in Gross & Net Proceeds Raised at Yesterday's Closing Price of $18.74 Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit,"

查看更多
Summit Therapeutics Raises $500 Million in Private Placement
Analyst Upgrades

Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16

Barclays analyst Etzer Darout maintains Summit Therapeutics with a Underweight and raises the price target from $13 to $16.

查看更多
Barclays Maintains Underweight on Summit Therapeutics, Raises Price Target to $16
Analyst Upgrades

HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $40

HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics with a Buy and lowers the price target from $50 to $40.

BusinessWire

Summit Therapeutics to Host ESMO Data Update & Third Quarter Earnings Call on October 20, 2025

Conference Call to be Held at 8:00am ET Summit Therapeutics Inc. (NASDAQ:SMMT) ("Summit," "we," or the "Company") will host an ESMO Data Update and Third Quarter Earnings Call on Monday, October 20, 2025, before the